Who is suitable for PBM therapy?

Is Photobiomodulation with Valeda Right for You? Discover the Ideal Patient for this Innovative Dry AMD Treatment

If you’ve been diagnosed with early-stage dry age-related macular degeneration (AMD), you might be wondering what options are available to protect your vision. LumiThera’s Valeda Light Delivery System offers an innovative treatment approach using photobiomodulation (PBM), a non-invasive therapy designed to slow the progression of dry AMD. But is Valeda the right solution for you? Let’s explore who can benefit most from this breakthrough technology.

Who is a Suitable Candidate for Valeda PBM Therapy?

The Valeda Light Delivery System is specifically designed for patients with early to intermediate stage dry AMD. If you’ve recently been diagnosed or are in the initial stages of the condition, Valeda offers a promising treatment option aimed at protecting and enhancing your vision.

Here’s a closer look at the key factors that make someone an ideal candidate for Valeda:

Diagnosed with Early-Stage Dry AMD
Valeda’s PBM therapy is intended for patients with early to intermediate dry AMD, where the retina’s cells begin to degenerate but significant vision loss has not yet occurred. It is in these early stages that Valeda can help prevent further damage and promote cellular repair, offering the greatest potential for preserving vision. If you are diagnosed with advanced dry AMD or wet AMD, alternative treatments may be more suitable.
Seeking Non-Invasive, Painless Treatment
One of the primary advantages of Valeda PBM therapy is its non-invasive nature. Unlike other AMD treatments that may require injections or surgeries, Valeda offers a painless, non-surgical alternative. If you prefer a treatment that doesn’t involve needles or invasive procedures, Valeda could be the right choice for you.
Looking for Proactive Vision Protection
Valeda is an ideal option for patients who want to take a proactive approach to managing their dry AMD before the condition worsens. By targeting the root cause—cellular degeneration and oxidative stress—Valeda aims to slow the progression of AMD and improve retinal function. If you’re seeking a treatment that doesn’t just manage symptoms but works to protect and enhance your vision, PBM therapy is a promising solution.
Committed to Regular Treatment Sessions
PBM therapy with Valeda is delivered over a series of sessions, typically over several weeks. Each session lasts only a few minutes, and the treatment is comfortable and straightforward. To achieve optimal results, patients need to commit to completing the entire course of therapy. If you are able to dedicate time to multiple treatment sessions, you’ll maximize your chances of experiencing the full benefits of Valeda.
Interested in Clinically Proven Therapies
Valeda is the first clinically proven PBM device for treating dry AMD, backed by extensive clinical trials demonstrating its safety and effectiveness. If you are interested in using an evidence-based treatment that has been tested and proven to improve visual function in early dry AMD patients, Valeda offers a trusted solution.

Who Might Not Be a Suitable Candidate for Valeda?

While Valeda is highly effective for early dry AMD patients, it may not be suitable for everyone. Patients with advanced dry AMD or wet AMD will require alternative treatments. If you have other serious eye conditions or health issues that affect your retina, our team will assess whether Valeda is the right choice for your unique situation.

Take the Next Step in Protecting Your Vision

If you’ve been diagnosed with early dry AMD and are looking for a proactive, non-invasive treatment to protect your vision, Valeda could be the right solution for you. With its innovative PBM therapy, LumiThera offers a safe, clinically proven way to slow the progression of AMD and help maintain your eye health.